Background: Inside the therapeutic algorithm of knee osteoarthritis (OA) it is included the Non-Arthroscopic Joint Lavage (NAJL) since around 1934 Burman reported that arthroscopies improved the symptoms. Current medical treatment strategies are aimed at pain reduction and symptom control rather than disease modification (1). The large variety of potentially interventions available has raised the need to assess their effectiveness. Objectives: To compare the short-term effectiveness among five treatment strategies in patients with symptomatic knee OA.
Methods: An open, controlled, randomized prospective study involving 150 patients of whom 76.7% were females. The average age was 65.37±8.35. Patients had knee OA according to American College of Rheumatology criteria, with Kellgren-Lawrence radiographic grades II-III. They were randomly assigned to five groups of treatment, 1)NAJL (n=30), 2)NAJL+hyaluronic acid (HA) (n=32), 3)NAJL+ corticosteroid (CS) (n=32), 4)HA (n=31), and 5)CS (n=25). Evaluations took place at baseline, one and three months. Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and Lequesne scores were recorded. Statistical analysis included mixed analysis of variance, with post-hoc comparisons with Sidak's adjustment, and multiple linear regression (MLR) to identify those possible factors associated to WOMAC total at 3 months. Results: Regarding WOMAC pain, significative differences were found in NAJL, at one month and at 3 months; and in NAJL+CS at one month. For WOMAC stiffness, there were significative differences in NAJL at one month and at 3 months; in NAJL+HA after one month and 3 months versus one month; and in NAJL+CS, at one month. For WOMAC function, significative differences were found in NAJL at one month and at three months; in NAJL+CS at one month; and in HA at 3 months. Regarding WOMAC total, significative differences were found in NAJL at one month (p<0.001) and at 3 months (p<0.001); and in NAJL+CS at one month (p=0.018). For Lequesne, significative differences were found in HA at one month (p=0.003) and at 3 months (p=0.019) versus baseline; and in CS, at one month (p<0.001). The WOMAC function at baseline, NAJL+HA, and infiltration with CS are the variables that show a significant association with WOMAC total at 3 months. The group that received NAJL+HA had poorer outcomes.
Conclusions:
One month after treatment, best outcomes were obtained with HA due to the results found in Lequesne scale when comparing HA versus NAJL+HA, and NAJL+CS. Three months after the treatment, the most effective modality treatment was NAJL; since we did find significant differences regarding articular stiffness, physical function and Lequesne scale. The treatment with NAJL+HA appears to be less effective than the other modalities. Background: Mud-bath therapy (MBT) is a non-pharmacological approach commonly used to treat osteoarthritis (OA). Several data indicate that MBT improve patient's symptoms (1), exerting a beneficial effect on pain and joint function, although the biological mechanisms involved in the therapeutic response are poorly defined.
Objectives: This study aimed to find molecular changes (proteins and mRNA variations) in patients with OA after MBT treatment.
Methods:
The study included 39 patients whit primary diffuse osteoarthritis, assigned to receive a cycle of mud-bath therapy over a period of 2 weeks added to usual pharmacologic treatment. Whole blood and serum were collected before and after standard MBT treatment: for each time points two pools of patients sera were analyzed by the direct antigen-labeling technology (RayBio ® Biotin Label-based Antibody Array, RayBiotech) obtaining a broad, panoramic view of protein expression. Using this semi-quantitative technique up to 1000 target proteins was simultaneously detected, making this approach ideally suited for proteomic studies. Again, pooled samples of mRNA were used to investigate genes expression and to perform the transcriptomic analysis using an highresolution array design that contains >6.0 million distinct probes, covering coding and non-coding transcripts (GeneChip ® HTA 2.0, Affymetrix).
Results: At the end of mud-bath therapy, using first a semi-quantitative approach, we observed in both biological replicates increased levels (>1.5 fold change) of: inhibin beta A subunit (INHBA), activin A receptor type 2B (ACVR2B), angiopoietin-1 (ANGPT1), beta-2-microglobulin (B2M), growth differentiation factor 10 (BMP-3b/GDF10), C-X-C motif chemokine ligand 5 (CXCL5), fibroblast growth factor 2 (FGF2), fibroblast growth factor 12 (FGF12), oxidized low density lipoprotein receptor 1 (OLR1), matrix metallopeptidase 13 (MMP13). We observed that some increased proteins belongs to the same family or pathway: INHBA, ACVR2B and BMP-3b are members of TGF-Beta superfamily; CXCL5 and MMP13 participate into IL-17 signaling pathway; FGF2 and FGF12 are proteins of FGF family. We are currently performing the transcriptome analysis, and the next step will be to correlate detected proteins with mRNA levels considering also post-transcriptional or epigenetic modifications. Finally we will validate these findings with other quantitative techniques (like ELISA and RT-PCR). Conclusions: Our first proteomic and broad spectrum analysis suggest the implication of molecular pathways involved in a wide variety of cellular functions such as gene expression modulation, differentiation, angiogenesis, tissue repair, acute and chronic inflammatory response which may explain the beneficial effects of MBT observed in osteoarthritis. This "omic" approach (proteomic and transcriptomic), generated a huge amount of data that is currently under statistical and bioinformatic analysis. Background: Increasing evidence indicates involvement of the pro-inflammatory cytokine TNF-α in hand osteoarthritis (OA) pathogenesis. Ten years clinical and radiologic follow-up of the BeSt study, a randomized trial primarily designed to investigate targeted treatment in rheumatoid arthritis (RA) patients, offered the unique opportunity to study the long-term effects of TNF inhibitors (TNFi) on the development and progression of hand OA. The distal interphalangeal joints (DIPs) are rarely affected in RA, which allowed to evaluate primary OA separately. Objectives: To investigate the effect of TNFi on incidental and progressive radiographic hand OA after 10-year follow-up in recent-onset RA patients. Methods: At baseline and 10-year follow-up 262 patients (mean age 52 years, 66% women) were available for radiologic assessment of hand OA. Eighteen interphalangeal joints (IPs) were scored for osteophytes (OP) using the Osteoarthritis Research Society International (OARSI) atlas (0-3; summated score 0-54), and according to the Kellgren-Lawrence (KL) scoring method (0-4; summated score 0-72). Incidental OA was defined as an increase ≥1 in summated OP score or ≥2 in summated KL score in absence of OA at baseline, and progressive OA as an increase ≥3 in summated OP or KL score in presence of OA at baseline, based on the smallest detectable change. TNFi treatment and disease activity score (DAS) were assessed on standardized visits at a three-monthly interval. Associations between duration of TNFi treatment in months and incidental and progressive OA were analyzed using generalized linear models with Poisson distribution and robust standard errors, while adjusting for age, gender, time averaged DAS, time averaged Sharp-van der Heijde score and hand OA severity at baseline. Results: Based on the OP score, 126 patients (48%) were classified with OA at baseline in the DIPs and 82 patients (31%) in the proximal IPs (PIPs). Incidental OA developed in 33% of patients in DIPs and in 42% in PIPs. Progressive OA occurred in 30% of patients in DIPs and in 38% in PIPs. Of patients with and without OA at baseline, irrespective of joint location, 63% and 55% were treated with TNFi, with a median treatment duration of 47 and 36 months, respectively. No effect of TNFi treatment duration was seen on incidental hand OA. On progressive hand OA, every month of TNFi treatment resulted in a reduced relative risk (RR) of OA progression in DIPs with a RR (95% confidence interval) of 0.987 (0.978-0.996), but not in the PIPs. The results from the analyses with the KL scoring method were comparable to the OP score, as shown in table 1. Conclusions: Prolonged TNFi treatment is associated with a reduced relative risk on radiologic hand OA progression in DIPs, but not in PIPs, after 10 years. Although the effect sizes are small, these results provide evidence for influence of TNF-α in hand OA pathogenesis. 
Background:
We have previously shown that people suffering with chronic pain in hand OA have activation of central brain pain processing centres localised to the anterior cingulate cortex, insular cortex and thalamus by functional neuroimaging (1) and algometry (2). Objectives: We hypothesised that hand OA subjects will have structural differences in 3 pain-processing regions of the brain -the anterior cingulate cortex (ACC), insular cortex and thalamus -based on activation of brain centres we have found previously (1). Our brain neuroimaging work was part of a randomised, placebo-controlled trial to assess the effect on clinical pain outcomes by intervention with centrally-acting analgesic agents: pregabalin or duloxetine. Methods: The primary outcome measures for our clinical trial were hand pain Numerical Rating Scale (NRS) and AUSCAN pain after 12 weeks' treatment. In secondary outcome analyses, participants with hand OA (n=28) underwent T1-weighted MRI of the brain before and after 12 weeks of treatment with pregabalin, duloxetine or placebo therapy. Grey matter brain structure was compared using FreeSurfer regional volumetric analysis and voxel-based morphometry (VBM) to age-matched controls (n=11), and evaluated for volume changes in the ACC, insular cortex and thalamus. Results: In our clinical trial, we observed clinically significant improvement in pregabalin, duloxetine and placebo treatment groups after 12 weeks (ANOVA p=0.0078). Most notably, pairwise comparisons for pregabalin vs placebo showed significant improvement for NRS pain and AUSCAN pain outcomes in the ITT analysis (p<0.05), but not for duloxetine vs placebo after 12 weeks' (p>0.05). Both voxel-wise and regional volumetric analyses demonstrated areas of reduced grey matter volume in the ACC of hand OA subjects, relative to control subjects, at baseline (p<0.05) (Figure 1 ). The structural differences in the ACC persisted following 12 weeks of treatment with pregabalin, duloxetine or placebo therapy (p<0.05). We did not observe structural differences in the insular cortex or thalamus in any of the three groups.
Conclusions:
We found that the ACC volume was reduced in participants with hand OA. The ACC is a key pain-processing region of the brain. Changes in ACC grey matter volume have previously been described in other painful conditions, but not hand OA. ACC grey matter volume reduction is thought to represent neural plasticity in chronic pain states. Our data supports the role of central sensitisation in hand OA and provides a rationale for the further investigation of centrallyacting analgesics in its management. Our trial demonstrated improvement in clinical endpoints for pain for pregabalin vs placebo and duloxetine vs placebo, respectively (p<0.05). However, structural differences in the ACC were still evident following 12 weeks of treatment with pregabalin or duloxetine. This may relate to the relatively short duration of treatment in our study. Alternatively, the baseline differences in the ACC may represent irreversible changes. Longitudinal studies with greater follow-up periods are necessary to further investigate this.
